The nomination committee of
The nomination committee proposes seven members of the board of directors and no deputy directors.
The nomination committee proposes that
Information about all persons proposed as members of the board of directors of Q-linea, the nomination committee's statement regarding the proposal for the board of directors and the nomination committee's complete proposal will be available on Q-linea's website, www.qlinea.com in connection with the issuance of the notice to attend the annual general meeting 2020, which is expected to be published around week 18.
The nomination committee has been appointed according to the principles adopted by the annual general meeting 2019 and consists of Öystein Engebretsen (
Uppsala,
The nomination committee of
For more information, please contact:
Jonas Jarvius, CEO, Q-linea AB
jonas.jarvius@qlinea.com
+46 (0)70-323 77 60
anders.lundin@qlinea.com
+46 (0)70-600 15 20
The information was submitted for publication, through the agency of the contact persons set out above, at
About Q-linea
Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea's vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.
https://news.cision.com/q-linea/r/the-proposal-by-the-nomination-committee-of-q-linea-ab--publ--for-election-of-members-of-the-board-o,c3096101
https://mb.cision.com/Main/17731/3096101/1235373.pdf
(c) 2020 Cision. All rights reserved., source